The landscape of obesity treatment is changing dramatically with the emergence of several novel injectable therapies. the GLP-1/GIP dual agonist, Cagrilintide , Survodutide , and this experimental compound https://nexaphresearchpeptides.com/product/nxp-2p-10-vials-kit-buy-nexaph-research-peptides/